𝛼SK or Search

ENTITY

Akeso (9926 HK)

367

Analysis

Health Care • China

Akeso is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative antibody drugs. It develops treatments for major diseases such as cancer, autoimmune diseases, inflammation, and metabolic diseases, with key products including cadonilimab, ivonescimab, and penpulimab. The company was founded in 2012 and is headquartered in Zhongshan, Guangdong, China.

more

Refresh

Exchange Announcement • 14 Oct 2026 06:06

Placing Of New Shares Under General Mandate

Exchange Announcement • 30 Sep 2026 17:03

2026 Interim Report

Exchange Announcement • 03 Sep 2026 07:01

Voluntary Announcement - Ivonescimab Meets Os Key Secondary Endpoint In Interim Analysis Of Harmoni-2 Study, Demonstrating Statistically Significant And Clinically Meaningful Benefit Versus Pembrolizumab In 1l Pd-L1-Positive Nsclc

Exchange Announcement • 27 Aug 2026 21:59

Interim Results Announcement For The Six Months Ended June 30, 2026

Exchange Announcement • 26 Aug 2026 07:00

Voluntary Announcement - Ak112-309/Harmoni-Gi1 Met Primary Endpoint Of Os Ivonescimab Plus Chemo Demonstrates Statistically Significant And Clinically Meaningful Os Benefit Versus Durvalumab Plus Chemo In 1l Btc

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x